香港股市 已收市

Smith & Nephew plc (SNN)

NYSE - Nasdaq 即時價格。貨幣為 USD。
加入追蹤清單
24.78+0.34 (+1.39%)
市場開市。 截至 03:38PM EDT。

Smith & Nephew plc

Building 5
Croxley Park Hatters Lane
Watford WD18 8YE
United Kingdom
44 1923 477 100
https://www.smith-nephew.com

版塊Healthcare
行業Medical Devices
全職員工18,452

高階主管

名稱頭銜支付行使價出生年份
Dr. Deepak S. Nath Ph.D.CEO & Director4.66M1972
Mr. John Terence RogersCFO & Executive Director1969
Mr. Paul ConnollyPresident of Global Operations1968
Mr. Andrew SwiftVice President of Investor Relations
Ms. Helen BarracloughGroup General Counsel & Company Secretary1979
Ms. Alison ParkesChief Compliance Officer & Compliance APAC1972
Mr. Joe MetzgerSenior Vice President of Marketing Services & Communications
Mr. Philip G. CowdyChief Corporate Development & Corporate Affairs Officer1967
Ms. Elga LohlerChief Human Resources Officer1968
Dr. Vasant Padmanabhan Ph.D.President of Research & Development and Ear, Nose & Throat1967
截止 2023年12月31日為止計算的金額,現金賠償則計算至上一個財政年度末止。薪資是指薪俸、獎金等。已行使價是指財政年度期間已行使的期權價值。貨幣為 USD。

描述

Smith & Nephew plc, together with its subsidiaries, develops, manufactures, markets, and sells medical devices and services in the United Kingdom and internationally. It operates through three segments: Orthopaedics, Sports Medicine & ENT, and Advanced Wound Management. The company offers knee implant products for knee replacement procedures; hip implants for revision procedures; trauma and extremities products that include internal and external devices used in the stabilization of severe fractures and deformity correction procedures; and other reconstruction products. It also provides sports medicine joint repair products comprise instruments, technologies, and implants to perform minimally invasive surgery, as well as treating soft tissue injuries and degenerative conditions of the shoulder, knee, hip, and small joints. In addition, the company offers arthroscopic enabling technologies comprising fluid management equipment for surgical access, high-definition cameras, digital image capture, scopes, light sources, and monitors to assist with visualization inside the joints, radio frequency, electromechanical and mechanical tissue resection devices, and hand instruments for removing damaged tissue; and ear, nose, and throat solutions. Further, it provides advanced wound care products for the treatment and prevention of acute and chronic wounds, which comprise leg wounds, diabetic and pressure ulcers, burns, and post-operative wounds; advanced wound bioactives, such as biologics and other bioactive technologies for debridement and dermal repair/regeneration, and regenerative medicine products, including skin, bone graft, and articular cartilage substitutes; and advanced wound devices, such as traditional and single-use negative pressure wound therapy, and hydrosurgery systems. The company serves the healthcare providers. Smith & Nephew plc was founded in 1856 and is headquartered in Watford, the United Kingdom.

公司管治

截至 2024年5月1日 止,Smith & Nephew plc 的 ISS 管治質素評分為 9。 Pillar 分數正在審核中:5;董事會:2;股東權利:9;現金賠償:10。

企業管治評分的資料提供: Institutional Shareholder Services (ISS). 評分將以 1 至 10 分顯示 (與指數或地區相關)。1 分表示較低的管治風險,而 10 分表示較高的管治風險。